Steadview Capital is a London and Hong Kong-based investment firm focused on growth-stage technology and technology-enabled companies globally. It operates across a wide range of sectors and typically invests at later rounds.

Steadview was an existing backer in Precision Neuroscience's 2023 Series B round, suggesting growth-stage exposure to BCI technology. The firm is not a dedicated healthcare or neurotech investor but participates selectively in high-conviction technology opportunities regardless of sector.